20S Proteasome Videos

Videos

Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM

01/10/2022

Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.

Jacob Laubach, MD, MPP,...

01/10/2022

Oncology

Videos

Dr Mithraprabhu Discusses Liquid Biopsy to Define Genomic Characteristics of Patients With MM

12/02/2021

Dr Sridurga Mithraprabhu, discusses liquid biopsy, which can be utilized to define the genomic characteristics of a patient with MM.

Dr Sridurga Mithraprabhu,...

12/02/2021

Oncology

Videos

Daratumumab-Based Triplet Therapy More Effective Than Doublet for MM

09/15/2021

Meletios Dimopoulos, MD, discusses the phase 3 APOLLO study on adding daratumumab to pomalidomide and low-dose dexamethasone for patients with MM.

Meletios Dimopoulos, MD,...

09/15/2021

Oncology

Videos

Dr Jain Discusses High-Risk MCL: Definition, Current Challenges, and Management

02/09/2021

Preetesh Jain, MBBS, MD, DM, PhD, discusses a study that explores the definition, current challenges, and management of high-risk MCL.

Preetesh Jain, MBBS, MD, DM,...

02/09/2021

Oncology

Videos

Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL

12/07/2020

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...

Constantine Tam, MBBS (Hons),...

12/07/2020

Oncology

$Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM$

Videos

Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM

12/05/2020

In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.

In this video, Dr Chari...

12/05/2020

Oncology

$Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL$

Videos

Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL

04/24/2020

Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.

Mehdi Hamadani, MD, weighs the...

04/24/2020

Oncology

Videos

Immunotherapies in Multiple Myeloma

10/25/2019

David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.

David E. Avigan, MD discusses...

10/25/2019

Oncology

Videos

Key Insights in Multiple Myeloma

02/27/2018

Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.

Drs Morton Coleman and Ruben...

02/27/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology